ライフサイエンスコーパス: in-stent restenosis

1 (bifurcations, chronic total occlusions, and in-stent restenosis).

2 ciated with major adverse clinical events or in-stent restenosis.

3 iction of progression of atherosclerosis and in-stent restenosis.

4 r brachytherapy for the treatment of diffuse in-stent restenosis.

5 ESS may have a limited role in in-stent restenosis.

6 the rate of recurrent restenosis in diffuse in-stent restenosis.

7 a 90Sr/90Y beta-source for the treatment of in-stent restenosis.

8 in patients undergoing treatment for diffuse in-stent restenosis.

9 nary radiation therapy reduces recurrence of in-stent restenosis.

10 seful adjunct for the clinical prevention of in-stent restenosis.

11 e for preventing recurrence in patients with in-stent restenosis.

12 giographic outcomes of patients with diffuse in-stent restenosis.

13 hought to be important for coronary arterial in-stent restenosis.

14 bo after interventional treatment of diffuse in-stent restenosis.

15 ogical data on the morphological features of in-stent restenosis.

16 percutaneous coronary intervention (PCI) for in-stent restenosis.

17 proliferation contribute to later stages of in-stent restenosis.

18 temic delivery nanoparticle PXL for reducing in-stent restenosis.

19 racoronary gamma-radiation reduces recurrent in-stent restenosis.

20 adiation for the prevention of recurrence of in-stent restenosis.

21 delaying, although probably not preventing, in-stent restenosis.

22 enting recurrent restenosis in patients with in-stent restenosis.

23 fective form of nonionizing energy to reduce in-stent restenosis.

24 become a useful approach to the treatment of in-stent restenosis.

25 onary radiation therapy for the treatment of in-stent restenosis.

26 on is a promising modality for inhibition of in-stent restenosis.

27 in the first 6 months after the treatment of in-stent restenosis.

28 emitters has been shown to reduce recurrent in-stent restenosis.

29 therapies aimed at reducing the incidence of in-stent restenosis.

30 e the effect of gamma-radiation on recurrent in-stent restenosis.

31 ere used to investigate the role of miRNA in in-stent restenosis.

32 l and angiographic outcomes of patients with in-stent restenosis.

33 stent oversizing may lower the frequency of in-stent restenosis.

34 mmatory approaches may be of value to reduce in-stent restenosis.

35 timal hyperplasia, reducing the incidence of in-stent restenosis.

36 minimizing the total stent length may reduce in-stent restenosis.

37 e most consistent predictors of angiographic in-stent restenosis.

38 on shortly after catheter-based treatment of in-stent restenosis.

39 strate effectiveness of strategies to reduce in-stent restenosis.

40 ed in a study of intracoronary radiation for in-stent restenosis.

41 smaller final MLD were strong predictors of in-stent restenosis.

42 SMC) hyperplasia is the most likely cause of in-stent restenosis.

43 in 25 stents without restenosis and 24 with in-stent restenosis.

44 f saphenous vein grafts, ostial lesions, and in-stent restenosis.

45 lates cell proliferation, a key component of in-stent restenosis.

46 , rs350104, and rs164390 affects the risk of in-stent restenosis.

47 y, saphenous vein grafts, ostial lesions, or in-stent restenosis.

48 e as useful tools in risk stratification for in-stent restenosis.

49 tents) consecutive symptomatic patients with in-stent restenosis.

50 %) could be attributed to segments with >70% in-stent restenosis.

51 rug-eluting stents has decreased the rate of in-stent restenosis.

52 ive in reducing neointimal proliferation and in-stent restenosis.

53 ntrolled targeting of MNPs with efficacy for in-stent restenosis.

54 obstruction post stenting, a disorder termed in-stent restenosis.

55 clinically on drug-eluting stents to inhibit in-stent restenosis.

56 efficacy in limiting recurrence of existing in-stent restenosis.

57 tomotic device stenosis, possibly similar to in-stent restenosis.

58 tive alternative to VBT for the treatment of in-stent restenosis.

59 lusions, planned two-stent bifurcations, and in-stent restenosis.

60 y supersede VBT as the therapy of choice for in-stent restenosis.

61 in the stented main branch that can lead to in-stent restenosis.

62 use of a stent to deliver a drug may reduce in-stent restenosis.

63 e plaque prolapse (2 cases); and (5) diffuse in-stent restenosis (1 case).

64 After successful catheter-based treatment of in-stent restenosis, 476 patients were randomly assigned

65 y-verified NA was observed in 40 stents with in-stent restenosis (62%), was more prevalent in DES tha

66 s of the stented segment without significant in-stent restenosis (71%).

67 To evaluate strategies to reduce in-stent restenosis, accurate measurement of in-stent ne

68 adiation for the prevention of recurrence of in-stent restenosis achieved similar rates of restenosis

69 f the main events responsible for bare metal in-stent restenosis after percutaneous coronary interven

70 lular composition of human coronary arterial in-stent restenosis after various periods of time follow

71 sty (ELCA)+adjunct PTCA for the treatment of in-stent restenosis and (via lesion matching) compared t

72 dary end points were the incidence of binary in-stent restenosis and 12-month major adverse cardiac e

73 stent fracture rate and its association with in-stent restenosis and adverse outcomes in the ACT-1 tr

74 ailure and in those undergoing treatment for in-stent restenosis and bifurcations.

75 In-stent restenosis and bypass graft failure are charact

76 een patients with superficial femoral artery in-stent restenosis and chronic limb ischemia were recru

77 nical outcome; however, due to potential for in-stent restenosis and high costs of stents, there is i

78 ed release of NO donor significantly reduces in-stent restenosis and is associated with increase in v

79 metal stents associates with a high risk of in-stent restenosis and need for future revascularizatio

80 y appear to be associated with high rates of in-stent restenosis and repeat target lesion revasculari

81 The incidence of repeat in-stent restenosis and target vessel revascularization

82 Drug-eluting stents reduce the occurrence of in-stent restenosis and the need for subsequent target v

83 lular matrix (ECM) remodeling contributes to in-stent restenosis and thrombosis.

84 nts with recurrent symptoms had angiographic in-stent restenosis and were successfully revascularized

85 e records of 473 patients who presented with in-stent restenosis and who were enrolled in various rad

86 s coronary dissection, no reflow phenomenon, in-stent restenosis, and stent thrombosis requires accur

87 Native atherosclerosis and in-stent restenosis are focal and evolve independently.

88 d reference segments during the treatment of in-stent restenosis are unknown.

89 Mechanisms of recurrence after treatment of in-stent restenosis are unknown.

90 e success of irradiation (brachytherapy) for in-stent restenosis argues that DNA-damage p53 responses

91 apy, renal failure, bifurcation lesions, and in-stent restenosis as significant correlates of ST (P<0

92 The primary end point of recurrent in-stent restenosis assessed by ultrasound at 6 months w

93 erior descending artery, length > or =20 mm, in-stent restenosis at baseline, and use of rotablator.

94 considerable reduction in the development of in-stent restenosis at the cost of an increased risk of

95 Five of the 11 patients had previous in-stent restenosis before CABG.

96 to be effective in the treatment of coronary in-stent restenosis, but data are limited regarding thei

97 Drug-eluting stents reduce the incidence of in-stent restenosis, but they result in delayed arterial

98 on therapy can effectively prevent recurrent in-stent restenosis by inhibiting neointimal formation w

99 ter stent implantation significantly reduces in-stent restenosis by inhibiting neointimal hyperplasia

100 Gene therapy to treat in-stent restenosis by using gene vector delivery from t

101 trasound (IVUS) analysis was performed in 30 in-stent restenosis cases treated with a 40-mm (90)Sr/Y

102 ntimal hyperplasia and significantly reduced in-stent restenosis compared with the control group by a

103 ctional atherectomy from 10 patients in whom in-stent restenosis complicated percutaneous revasculari

104 te as compared with balloon angioplasty, but in-stent restenosis continues to be an important clinica

105 Unfortunately, in-stent restenosis continues to plague this procedure,

106 for the ability to predict the occurrence of in-stent restenosis defined as a diameter stenosis > or

107 iabetics are at increased risk of developing in-stent restenosis for unclear reasons.

108 udy was performed to determine predictors of in-stent restenosis from a high volume, single-center pr

109 in the PEB group and also in subgroups with in-stent restenosis >10 mm (0.05 versus 0.26 mm; P=0.000

110 Of 252 eligible patients in whom in-stent restenosis had developed, 131 were randomly ass

111 In-stent restenosis has a high recurrence rate after per

112 However, its impact on in-stent restenosis has not been systematically investig

113 f systemic pharmacotherapy aimed at reducing in-stent restenosis have been consistently disappointing

114 sed stent use and the difficulty in managing in-stent restenosis have provided the impetus to develop

115 ibitors, including atherothrombotic disease, in-stent restenosis, heart failure, and sepsis.

116 nts has demonstrated efficacy for preventing in-stent restenosis; however, both the inflammatory effe

117 he Gamma-1 trial, coronary brachytherapy for in-stent restenosis improved clinical outcomes but incre

118 adiation for the prevention of recurrence of in-stent restenosis in native coronaries and saphenous v

119 A total of 120 patients with diffuse in-stent restenosis in native coronary arteries (lesion

120 tal of 120 consecutive patients with diffuse in-stent restenosis in native coronary arteries and vein

121 ectively, with late (> 1 year) TSR driven by in-stent restenosis in only 3 patients (1.7%).

122 gamma-radiation therapy for the treatment of in-stent restenosis in patients with bypass grafts.

123 ding stents is associated with high rates of in-stent restenosis in patients with diabetes mellitus.

124 myocardial CTP improves diagnosis of CAD and in-stent restenosis in patients with stents compared wit

125 A total of 120 patients with in-stent restenosis in saphenous-vein grafts, the majori

126 al novel therapeutic approach for inhibiting in-stent restenosis in such patients.

127 nalysis, ACS was an independent predictor of in-stent restenosis in the cohort treated with bare-meta

128 a intracoronary radiation therapy (ICRT) for in-stent restenosis (IRS).

129 In-stent restenosis is a major limitation of intracorona

130 In-stent restenosis is associated with a high incidence

131 Intracoronary radiation for patients with in-stent restenosis is associated with a high rate of LT

132 DCBA for superficial femoral artery in-stent restenosis is associated with less recurrent re

133 Furthermore, if the capacity of DES to treat in-stent restenosis is confirmed in randomized trials, t

134 the past few years, it has become clear that in-stent restenosis is largely due to the migration and

135 diabetes mellitus (DM), especially IDDM, on in-stent restenosis is not known.

136 As a result, in-stent restenosis is now an important clinical problem

137 Serial IVUS studies have shown that in-stent restenosis is secondary to intimal hyperplasia.

138 ic, and histological features of concomitant in-stent restenosis (ISR) and cardiac allograft vasculop

139 aneous treatment of drug-eluting stent (DES) in-stent restenosis (ISR) and the correlates for recurre

140 Recent successes in the treatment of in-stent restenosis (ISR) by drug-eluting stents belie t

141 As a result, in-stent restenosis (ISR) has become a widespread proble

142 for bare metal stent and drug-eluting stent in-stent restenosis (ISR) have not been established.

143 Re-stenting of in-stent restenosis (ISR) improves acute angiographic re

144 Clinical presentation of bare metal stent in-stent restenosis (ISR) in patients undergoing target

145 In-stent restenosis (ISR) is a novel pathobiologic proce

146 nt of patients with drug-eluting stent (DES) in-stent restenosis (ISR) is more challenging than that

147 Treatment of in-stent restenosis (ISR) is still challenging.

148 ry gamma-irradiation in preventing recurrent in-stent restenosis (ISR) is well established.

149 It is unclear whether PCI of in-stent restenosis (ISR) lesions in degenerated SVGs is

150 ual distribution of gamma radiation in human in-stent restenosis (ISR) lesions, and 2) to analyze the

151 The angiographic presentation of in-stent restenosis (ISR) may convey prognostic informat

152 ectomy for de novo atherosclerosis (n=55) or in-stent restenosis (ISR) of a bare metal stent (n=34).

153 outcomes of patients who developed coronary in-stent restenosis (ISR) or stent thrombosis (STH) insi

154 percutaneous coronary intervention (PCI) for in-stent restenosis (ISR) randomized to short (6 months)

155 In-stent restenosis (ISR) remains a difficult problem in

156 nt of patients with drug-eluting stent (DES) in-stent restenosis (ISR) remains a major challenge.

157 Management of patients with in-stent restenosis (ISR) remains an important clinical

158 examined long-term outcomes of patients with in-stent restenosis (ISR) who underwent different percut

159 s in 66 patients with native coronary artery in-stent restenosis (ISR) who were treated with (192)Ir

160 phic angiography (CTA) and their relation to in-stent restenosis (ISR), stent fracture (SF), and over

161 x lesions also introduced a new problem: DES in-stent restenosis (ISR), which occurs in 3% to 20% of

162 erapy (IRT) is the only proven treatment for in-stent restenosis (ISR).

163 ts of vascular brachytherapy (VBT) on ostial in-stent restenosis (ISR).

164 radiation therapy (IRT) for the treatment of in-stent restenosis (ISR).

165 tion therapy (IRT) in diabetic patients with in-stent restenosis (ISR).

166 racoronary gamma-radiation reduces recurrent in-stent restenosis (ISR).

167 tion of intracoronary irradiation to prevent in-stent restenosis (ISR).

168 ntages over other modalities in treatment of in-stent restenosis (ISR).

169 in graft (SVG) versus native coronary artery in-stent restenosis (ISR).

170 gioplasty, PTCA) in the treatment of diffuse in-stent restenosis (ISR).

171 ry gamma-radiation therapy reduces recurrent in-stent restenosis (ISR).

172 ary angioplasty [PTCA]) for the treatment of in-stent restenosis (ISR).

173 ES) in patients with bare-metal stents (BMS) in-stent restenosis (ISR).

174 EES in patients with bare-metal stents (BMS) in-stent restenosis (ISR).

175 intervention (PCI) can lead to a decrease in in-stent restenosis (ISR).

176 reatment of superficial femoral artery (SFA) in-stent restenosis (ISR).

177 cted distal left main coronary artery (UDLM) in-stent restenosis (ISR).

178 luting stent (SES) implantation treatment of in-stent restenosis (ISR).

179 ary radiation therapy (IRT) in patients with in-stent restenosis (ISR).

180 Although MSA is a consistent predictor of in-stent restenosis, its predictive value in BMS is stil

181 t were 6 to 10 mm proximal and distal to the in-stent restenosis lesion.

182 ) extended >10 mm proximal and distal to the in-stent restenosis lesion.

183 confidence interval, 0.98-12.20; P=0.05) and in-stent restenosis lesions (odds ratio, 5.30; 95% confi

184 ion protocol of (90)Sr/Y radiation to native in-stent restenosis lesions may provide substantial inhi

185 1025 consecutive native coronary artery, non-in-stent restenosis lesions undergoing PCI, 72 hematomas

186 th treatment of chronic total occlusions and in-stent restenosis lesions, and had higher 12-month maj

187 More careful consideration of the type of in-stent restenosis may aid in identifying when alternat

188 Balloon angioplasty of in-stent restenosis may, therefore, fail due to ECM chan

189 d stent struts were also assessed in the pig in-stent restenosis model.

190 roliferative activity, in a porcine coronary in-stent restenosis model.

191 When severe forms of in-stent restenosis occur, they tend to present earlier

192 At a mean follow-up of 13+/-5 months, repeat in-stent restenosis occurred in 28% of patients with TVR

193 % in drug-eluting stents, with mean diameter in-stent restenosis of 36% and 8%, respectively.

194 nity-based institutions in 396 patients with in-stent restenosis of a previously implanted bare-metal

195 travascular gamma radiation in patients with in-stent restenosis of saphenous-vein bypass grafts.

196 The process of in-stent restenosis parallels wound healing responses.

197 Treatment of in-stent restenosis presents a critical limitation of in

198 The binary in-stent restenosis rate was 2% for the sirolimus stent

199 ent thrombosis-related MI (n=63; 24.0%), and in-stent restenosis-related MI (n=58; 22.1%).

200 Intimal hyperplasia and subsequent in-stent restenosis remain a major limitation after sten

201 In-stent restenosis remains a challenging problem, and i

202 estenosis compared with balloon angioplasty, in-stent restenosis remains a major clinical problem.

203 ever, arterial reobstruction after stenting, in-stent restenosis, remains an important problem.

204 These findings support the notion that in-stent restenosis results from SMC hyperplasia and sug

205 In-stent restenosis results primarily from neointimal hy

206 ion in circulating lymphocytes and increased in-stent restenosis risk (OR, 1.43; 95% CI, 1.00-1.823;

207 on used as adjunct therapy for patients with in-stent restenosis significantly reduces both angiograp

208 Using a porcine coronary artery model of in-stent restenosis, single Palmaz-Schatz stents were im

209 rom normal vessels (n-VSMCs) and angioplasty/in-stent restenosis sites (r-VSMCs).

210 For in-stent restenosis, the benefit of DCBA over POBA remai

211 After conventional treatment of in-stent restenosis, the incidence of recurrent clinical

212 a reduction in re-stenting for patients with in-stent restenosis treated with gamma-radiation is well

213 ee events were potentially related to BVS: 1 in-stent restenosis (treated 7 months after pPCI with dr

214 ail" (192)Ir intracoronary brachytherapy for in-stent restenosis, treatment with (192)Ir delays the t

215 The Washington Radiation for In-Stent Restenosis Trial (WRIST) PLUS, which involved 6

216 R patients from the Washington Radiation for In-Stent restenosis Trial (WRIST) that met the following

217 In the Washington Radiation for In-Stent restenosis Trial (WRIST), patients with in-sten

218 rachytherapy in the Washington Radiation for In-Stent Restenosis Trial (WRIST).

219 ere enrolled in the Washington Radiation for In-Stent Restenosis Trial (WRIST; ISR length, 10 to 47 m

220 The Washington Radiation for In-Stent Restenosis Trial for long lesions (Long WRIST)

221 The Washington Radiation for In-Stent Restenosis Trial is a double-blinded randomized

222 ery ISR from WRIST (Washington Radiation for In-Stent Restenosis Trial) and 31 patients with SVG ISR

223 study, BETA WRIST (Washington Radiation for In-Stent restenosis Trial) was designed to examine the e

224 lled in (1) Long WRIST (Washington Radiation In-Stent Restenosis Trial), a double-blind, placebo-cont

225 essel ISR in WRIST (Washington Radiation for In-Stent Restenosis Trial), in which patients with ISR w

226 In the Washington Radiation for In-Stent Restenosis Trial, patients with ISR treated wit

227 332 patients with in-stent restenosis underwent successful coronary interv

228 One hundred thirty patients with in-stent restenosis underwent successful coronary interv

229 ted to dramatically reduce the recurrence of in-stent restenosis, up to 24% of these patients will st

230 egy against vaso-occlusive disorders such as in-stent restenosis, vein-graft stenosis, and transplant

231 In-stent restenosis was 0 in the proximal LAD sirolimus-

232 In-stent restenosis was angiographically documented in 2

233 In-stent restenosis was defined as a stent area stenosis

234 secutive series of 456 coronary lesions with in-stent restenosis was evaluated for the type of resten

235 Underlying in-stent restenosis was present in only 4 (31%) of 13 ca

236 tent restenosis Trial (WRIST), patients with in-stent restenosis were first treated with conventional

237 cember 1997 and July 1998, 252 patients with in-stent restenosis were randomized to receive brachythe

238 Late lumen loss and in-stent restenosis were the result of neointimal tissue

239 by offering reserve coronary circulation, if in-stent restenosis were to occur in the treated left ma

240 enter, randomized trial of 384 patients with in-stent restenosis who were enrolled between February 2

241 l occlusion (LTO, >30 days) in-patients with in-stent restenosis who were treated with intracoronary

242 ic choice for patients with complex, diffuse in-stent restenosis who would otherwise have a very poor

243 ly performed, the prevalence of renal artery in-stent restenosis will increase.

244 fect resulted in a significant inhibition of in-stent restenosis with a relatively low dose of MNP-en

245 (PEPCAD DES-Treatment of DES-In-Stent Restenosis With SeQuent(R) Please Paclitaxel El

246 urrent restenotic lesion, after treatment of in-stent restenosis with vascular brachytherapy in the W

247 ng may potentially reduce costs and rates of in-stent restenosis without compromising the quality of

248 crog/mm2, reduced angiographic indicators of in-stent restenosis without short- or medium-term side e